Avacta Share Discussion Threads

[coley15] 21/5/2025 17:22

Who's this Tom? He sounds a visionary

[dudishes] 21/5/2025 16:49

Tom has this as a zero.

[thiopia] 21/5/2025 16:12

Where is Myles McNulty ?

[sandcrab2] 21/5/2025 15:52

All predicted by Tom when the price was 250p
I think he said he might buy when the price hit 20p
A £50m fundraise at 20p might be the way forward now

[1347] 21/5/2025 08:48

SP sliding below 30p now, death spiral means it will slide towards 20 p, apart from the spike when they need to forwards sell the next conversion. How's the Phase II trial going? Any date for even starting it (apart from them saying it would be in 2024)?

[ohwhatfun] 20/5/2025 16:59

There was a bit if a clue re the likely fund raise date

results for year ended December 31, 2024 ("FY24") on May 29, 2025.

[ohwhatfun] 20/5/2025 16:50

The Bull crew are probably amassed in various private hype pump telegram type chats. Some of which will be pumping and selling.

A reminder.

This tech (the leftovers) is US abandoned tech. Abandoned by a co founder who was worth $2 billion.

The start point that hooked retail was LFTs, certain social media posters with good followings, pumped the hell out of it, completely avoiding the failures, just flipping to the next hype part. Pumping it £1 plus walking straight into a 50p raise which some here publicly warned about.

Arisaph ex staff came along to Avacta with the prodrug link and left just as quickly.

The share price foundations are built on a mass of retail blinkered punters, no doubt a good portion of which are geared and sweating.

Avacta need cash soon, plenty of it and in an awful market, with no solid backers.

Bloodbath potential near term. There is no near story to push out to fend it off, it’s looking grim.

That’s the reality of it. At some point the begging bowl will be out, insiders will know, and the market will dump stock onto retail, forward selling.

Good cash made by traders but soon it will crash on a discounted raise, IF they can find enough backers.

[dudishes] 20/5/2025 16:45

Dead ringer for a 2nd short. 33p

[bones698] 20/5/2025 16:21

This company reminds me of destiny to some degree . Far too much priced in for things that are years away and will take lots of cash to get to . These companies have to get to that point first and blowing millions in big losses and bloated expenses isn't the way to get there . I suspect avacta will need several more raises given how early their drugs are in development and that will continue to drive the share price lower. Poor management here will result in a similar story unfolding to that of dest imo . Their products look good though but to far away at this point to be worth investing in

Predicted the fall from over 110p and I don't think this is the bottom yet far from it . If it survives a couple of years that might be the time to invest imo

[viking24] 20/5/2025 08:22

Pfizer signed a mega licensing deal worth over $6 billion with Chinese firm 3SBio, securing ex-China rights to the latter's PD-1/VEGF-targeting bispecific antibody SSGJ-707 in oncology indications. The news sent 3SBio's stock surging over 30% at the Hong Kong exchange on Tuesday.The deal announced Monday, grants Pfizer exclusive global development, manufacturing and commercialisation rights for SSGJ-707, excluding China, with an option to acquire commercialisation rights within China at a later date. Under the agreed terms, Pfizer will make an upfront payment of $1.25 billion - a new record for licensing pacts with Chinese biotechs. Additionally, 3SBio will be eligible for potential milestone payments reaching $4.8 billion, alongside tiered double-digit sales royalties.

[sandcrab2] 15/5/2025 19:27

So pleased for PWhite and his investment in IRON

£60 million!!!

“ Align Research
@AlignResearch
Fantastic to see Ironveld #IRON back today.
Night and day is an understatement ref stewardship now under Dr J Wardle and the previous incumbents -Eales & Clarke. We maintain a sale is endgame in next 18 months & hopefully around £60m which equates to approx 0.40p on
11:21 am · 1 Apr 2025”

[cheshire pete] 14/5/2025 08:29

So am I Rajraj. Wonder how many of the FUDsters on here will submit questions for the upcoming webinair?
My guess is a big fat zero, as they're not really interested in the company just trying to persuade the weak and gullible to sell up.

[terminator101] 12/5/2025 07:25

Morning gerbils. Just checking in on this death spiral pish. All time low you say? Don't worry though as there is only another £28 million of death spiral to be dumped. Target price 0p IMO

[pwhite73] 11/5/2025 12:23

Hi Rajraj b - Pleased to hear you're still around. I agree all good things come to those who wait BUT they must be good in the first place.

JakNife - Many have considered me ill in the head for a good number of years. Other than that I'm fine and haven't been ill.

[rajraj b] 10/5/2025 18:49

I'm still here PWhite. Waiting patiently. All good things come to those who wait.

[jaknife] 08/5/2025 15:58

Welcome back PWhite73, I hope that you are feeling well? I had heard that you had been ill.

[pwhite73] 08/5/2025 15:56

Whatever happened to Rajraj b. I always liked him. Has he seen the light at last?

[1347] 03/5/2025 08:37

Or maybe they were located next to the burger stall?

[pwhite73] 03/5/2025 07:33

vertigo - "Both posters are mobbed five deep"

Is that because the five people who approached were told to form a single file queue?

[vertizeasun] 29/4/2025 07:55

Christina Coughlin
@coughlin582
·
11h
Replying to
@avacta
Both posters are mobbed five deep within 20 minutes of the session starting. 👍🏻

#BestTeamEver
#LetsDoThis
#AVCT

[vertizeasun] 29/4/2025 07:51

Conversation

Avacta
@avacta
The preclinical and translational data being presented on two posters by the Avacta team today at #AACR25 are now available to view on our website at A third poster, on safety and efficacy data for AVA6000, will go live at the same time tomorrow. #AVCT

[viking24] 28/4/2025 15:43

I would expect a counter bid for the following acquisition:German pharmaceutical group Merck KGaA has agreed to acquire US biotech company Springworks Therapeutics in a transaction valuing Springworks' equity at USD 3.9bn.